Johnson & Johnson-backed cancer biospy developer Inivata has added $35m to a series C round anchored by $25m from NeoGenomics in May.
Inivata, a UK-based precision cancer diagnostics spinout of University of Cambridge and Cancer Research UK, increased a series C round featuring cancer diagnostics service provider NeoGenomics to $60m today.
Healthcare investment firm Soleus Capital is leading the round, which includes IP Group, Janus Henderson Investors and Farallon Capital. The first $25m was provided by NeoGenomics as part of a strategic collaboration agreement in May 2020.
Founded in 2014, Inivata has created a highly sensitive personalised assay called Radar that…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
